THNR
Amplify Weight Loss Drug & Treatment ETF
Amplify Weight Loss Drug & Treatment ETF seeks to provide investors with exposure to companies involved in the development and commercialization of weight loss drugs and treatments.
Global
EQUITY
Passive
MANAGEMENT STYLE
$ 4.0 M
ASSETS UNDER MGMT
59 bp
EXPENSES
Fund Basics
| Inception date | May 20, 2024 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| NOVO-NORDISK A/S-SPONS ADR | 13.5 % |
| ELI LILLY & CO | 11.3 % |
| REGENERON PHARMACEUTICALS | 6.7 % |
| AMGEN INC | 6.2 % |
| CHUGAI PHARMACEUTICAL CO LTD | 6.1 % |
| ARROWHEAD PHARMACEUTICALS, INC. | 5.8 % |
| INNOVENT BIOLOGICS, INC. | 5.3 % |
| ROCHE HOLDING AG | 5.0 % |
| CHINA PHARMACEUTICAL GROUP | 5.0 % |
| PFIZER INC | 4.9 % |
Constituent Breakdown
| Number of holdings | 17 |
| Herfindahl-Hirschman Index | 655 |
| Wgt avg mkt cap (mns) | $236,114 |
| Large cap (>$10bn) | 86.5% |
| Mid cap ($2-10bn) | 11.2% |
| Small cap (<$2bn) | 0.0% |
| Developed mkts. | 83.9% |
| Emerging mkts. | 6.7% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 48.5 % |
 |
DENMARK | 15.3 % |
 |
JAPAN | 10.5 % |
 |
CHINA | 5.3 % |
 |
HONG KONG | 5.0 % |
 |
BRITAIN | 4.8 % |
 |
SOUTH KOREA | 1.3 % |
Historical Performance
Standardized Performance (as of 03/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | -2.5% | 14.1% | -- | -- | -- | -- | -- | -1.7% |
| Dividend Yield | 0.0% | 0.0% | -- | -- | -- | -- | -- | 0.5% |
| Total Returns | -2.5% | 14.1% | -- | -- | -- | -- | -- | -1.2% | Ann. Volatility | 20.3% | 22.1% | -- | -- | -- | -- | -- | 19.4% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.70 | 36% |
| MSCI EAFE | 0.87 | 49% |
| MSCI Emg Mkts | 0.64 | 34% |
Liquidity Measures
| Avg. volume (000) | 1 |
| ADV traded (mns) | $0 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.58% |
Technical Indicators
| 30d moving avg. (EMA) | $24.69 |
| Relative strength (RSI) | 46 |
| MACD/Signal | -0.04/-0.03 |
| Bollinger Bands (Upper/Lower) | $25.37/$23.91 |
| Short interest (% of AUM) | 3.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. THNR |
Expenses vs. THNR |
ALTAR Score™ vs. THNR |
|---|---|---|---|---|
| OZEM | Roundhill GLP-1 & Weight Loss ETF | 58.3% | 0 bp | -0.3% |
| MEDX | Horizon Kinetics Medical ETF | 35.1% | +26 bp | -5.1% |
| PPH | VanEck Pharmaceutical ETF | 30.4% | -23 bp | +1.6% |
| HRTS | Tema Heart & Health ETF | 29.8% | +16 bp | -3.3% |
| XLV | Health Care Select Sector SPDR | 28.3% | -51 bp | +0.7% |
| IYH | iShares U.S. Healthcare ETF | 28.1% | -19 bp | -0.1% |
| IXJ | iShares Global Healthcare ETF | 27.6% | -17 bp | +0.5% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 27.2% | +1 bp | +1.1% |
| VHT | Vanguard Health Care ETF | 27.2% | -50 bp | -0.9% |
| PJP | Invesco Pharmaceuticals ETF | 27.0% | -2 bp | +1.6% |
Risk and Returns: THNR vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 4/30/2026
Peer Group Comparison Sample data. Subscribe for access.
Price-to-Earnings
Price-to-Sales
Price-to-Book Value
Price-to-Cash Flow
Price-to-Growth
Dividend Yield
Historical Valuation Trends Sample data. Subscribe for access.
SHOWING:
Price-to-Earnings
Price-to-Earnings
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
6.7%
ALTAR SCORE™
81st
PERCENTILE
SPECULATIVE
ETFRC RATING
There are 586 funds in the Global Equity category with an average
ALTAR Score™ of 4.4% and a standard deviation
of 2.7%. THNR's ALTAR Score™ is approximately 0.9 standard
deviations above the category average. This places THNR in the 81st percentile
among funds in the category.
Sell-Side Consensus
$29.75
PRICE TARGET
+26.1%
UPSIDE